Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy.

Chemical Science
Giambattista TestolinMark Brönstrup

Abstract

There is an alarming scarcity of novel chemical matter with bioactivity against multidrug-resistant Gram-negative bacterial pathogens. Cystobactamids, recently discovered natural products from myxobacteria, are an exception to this trend. Their unusual chemical structure, composed of oligomeric para-aminobenzoic acid moieties, is associated with a high antibiotic activity through the inhibition of gyrase. In this study, structural determinants of cystobactamid's antibacterial potency were defined at five positions, which were varied using three different synthetic routes to the cystobactamid scaffold. The potency against Acinetobacter baumannii could be increased ten-fold to an MIC (minimum inhibitory concentration) of 0.06 μg mL-1, and the previously identified spectrum gap of Klebsiella pneumoniae could be closed compared to the natural products (MIC of 0.5 μg mL-1). Proteolytic degradation of cystobactamids by the resistance factor AlbD was prevented by an amide-triazole replacement. Conjugation of cystobactamid's N-terminal tetrapeptide to a Bodipy moiety induced the selective localization of the fluorophore for bacterial imaging purposes. Finally, a first in vivo proof of concept was obtained in an E. coli infection mouse ...Continue Reading

References

May 8, 2003·Journal of the American Chemical Society·Dorte Renneberg, Peter B Dervan
Jul 2, 2003·Current Opinion in Structural Biology·Peter B Dervan, Benjamin S Edelson
Feb 12, 2008·Journal of Medicinal Chemistry·Rosemarie O'Shea, Heinz E Moser
Jun 23, 2010·Proceedings of the National Academy of Sciences of the United States of America·Ying KongJeffrey D Cirillo
Jan 15, 2011·Clinical Microbiology Reviews·Lynn L Silver
Sep 10, 2011·Applied Microbiology and Biotechnology·Frédéric CollinAnthony Maxwell
Jun 13, 2013·Journal of Medicinal Chemistry·Matthew F BrownRichard P Zaniewski
Feb 4, 2014·Nature Medicine·Frank J HernandezJames O McNamara
Oct 24, 2014·Science Translational Medicine·Xiaojian Wang, Niren Murthy
Jan 20, 2015·Nature Chemical Biology·Stéphane CociancichRoderich D Süssmuth
Jun 10, 2015·Journal of the American Chemical Society·Laura ViewegRoderich D Süssmuth
Jul 4, 2015·Nature Reviews. Drug Discovery·Ruben TommasiAlita A Miller
Jun 30, 2016·The Journal of Antibiotics·Mark S ButlerMatthew A Cooper
Dec 10, 2016·Chemical Communications : Chem Comm·Qingyang ZhangHai-Yu Hu
May 11, 2017·Nature·Michelle F RichterPaul J Hergenrother
May 23, 2017·Natural Product Reports·P Klahn, M Brönstrup
Jul 4, 2017·Natural Product Reports·Bradley S MooreMark Brönstrup
Jul 6, 2017·Drug Discovery Today·Elisa BonandiDaniele Passarella
Sep 7, 2017·Chemistry : a European Journal·Leonard von EckardsteinRoderich D Süssmuth
Dec 26, 2017·The Lancet Infectious Diseases·Evelina TacconelliUNKNOWN WHO Pathogens Priority List Working Group
Aug 8, 2018·Nature Communications·Lida RostockRoderich D Süssmuth

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
confocal microscopy
Fluorescence

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.